Process for preparing purified drug conjugates
The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
1. A process for preparing an antibody-maytansinoid conjugate comprising the steps of:
(a) contacting a monoclonal antibody with a bifunctional crosslinking reagent at room temperature to covalently attach a linker to the antibody and thereby prepare a first mixture comprising antibodies having linkers bound thereto,
(b) subjecting the first mixture to tangential flow filtration, adsorptive chromatography, adsorptive filtration, selective precipitation, or combinations thereof and thereby prepare a purified first mixture of antibodies having linkers bound thereto,
(c) conjugating maytansinoid to the antibodies having linkers bound thereto in the purified first mixture by reacting the antibodies having linkers bound thereto with maytansinoid-in a solution having a pH of about 4 to about 6 at room temperature to prepare a second mixture comprising (i) antibodies chemically coupled through the linker to the maytansinoid, (ii) free maytansinoid, and (iii) reaction by-products, and
(d) subjecting the second mixture to tangential flow filtration and/or adsorptive chromatography to purify the antibodies chemically coupled through the linkers to the maytansinoid from the other components of the second mixture and thereby prepare a purified second mixture of antibodies chemically coupled through the linkers to the maytansinoid, with the proviso that if the first mixture is subjected to tangential flow filtration in step (b), the second mixture is not subjected to adsorptive chromatography in step (d).
2. The process of claim 1 , wherein the antibody is a humanized monoclonal antibody.
3. The process of claim 1 , wherein the antibody is selected from trastuzumab, bivatuzumab, sibrotuzumab, CNTO95 and rituximab.
4. The process of claim 1 , wherein the maytansinoid comprises a thiol group.
5. The process of claim 1 , wherein the maytansinoid is N 2′ -deacetyl-N 2′ -(3-mercapto-1-oxopropyl)-maytansine (DM1) or N 2′ -deacetyl-N 2′ -(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4).
6. The process of claim 1 , wherein the antibody is chemically coupled to the maytansinoid via chemical bonds selected from disulfide bonds, acid labile bonds, photolabile bonds, peptidase labile bonds, thioether bonds, and esterase labile bonds.
7. The process of claim 1 , wherein the solution in step (c) comprises sucrose.
8. The process of claim 1 , wherein the solution in step (c) comprises a buffering agent selected from a citrate buffer, an acetate buffer, a succinate buffer, and a phosphate buffer.
9. The process of claim 1 , wherein the maytansinoid is N 2′ -deacetyl-N 2′ -(3-mercapto-1-oxopropyl)-maytansine (DM1).
10. The process of claim 1 , wherein the bifunctional crosslinking reagent is selected from N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxy-(6-amidocaproate), (LC-SMCC), κ-maleimidoundecanoic acid N-succinimidyl ester (KMUA), γ-maleimidobutyric acid N-succinimidyl ester (GMBS), ε-maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N-(α-maleimidoacetoxy)-succinimide ester (AMAS), succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH), N-succinimidyl 4-(p-maleimidophenyl)-butyrate (SMPB), and N-(p-maleimidophenyl)isocyanate (PMPI), N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), N-succinimidyl iodoacetate (SIA), N-succinimidyl bromoacetate (SBA), and N-succinimidyl 3-(bromoacetamido)propionate (SBAP).
11. The process of claim 1 , wherein the bifunctional crosslinking reagent is selected from N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), and N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC).
12. The process of claim 1 , wherein the antibody is trastuzumab, the maytansinoid is N2′-deacetyl-N2′-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4) and the bifunctional crosslinking reagent is N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB).
13. The process of claim 1 , wherein the antibody is trastuzumab, the maytansinoid is N 2 ′-deacetyl-N 2 ′-(3-mercapto-1-oxopropyl)-maytansine (DM1) and the bifunctional crosslinking reagent is N-succinimidyl 4-maleimidomethyl)cyclohexanecarboxylate (SMCC).
14. The process of claim 1 , wherein the tangential flow filtration is diafiltration.
15. The process of claim 14 , wherein the diafiltration is performed using a phosphate buffer.
16. The process of claim 1 , wherein the adsorptive chromatography is ion exchange chromatography.
17. The process of claim 16 , wherein the ion exchange chromatography is performed using sulphopropyl or carboxymethyl chromatography resin.
18. The process of claim 16 , wherein the ion exchange chromatography is performed using quaternary ammonium chromatography resin.
19. The process of claim 1 comprising subjecting the first mixture to tangential flow filtration in step (b).
20. The process of claim 19 , wherein the tangential flow filtration is diafiltration.
21. The process of claim 1 , wherein the tangential flow filtration in step (d) is diafiltration.
22. The process of claim 1 , wherein the adsorptive chromatography in step (d) is ion exchange chromatography.
23. The process of claim 22 , wherein the ion exchange chromatography is performed using sulphopropyl or carboxymethyl chromatography resin.
24. The process of claim 1 , wherein the linker is a cleavable linker.
25. The process of claim 1 , wherein the antibody is selected from an antibody that binds Cluster of Differentiation 56, an antibody that binds Cluster of Differentiation 33, an antibody that binds Cluster of Differentiation 19, an antibody that binds C242 Cancer Antigen, and an antibody that binds mucin-1.